Agnes Septiani and Pande Putu Ayu Patria Dewi and Anita Widyoningroem and Anggraini Dwi Sensusiati and Muhammad Yamin (2019) The relationship between Epidermal Growth Factor Receptor (EGFR) mutation and computed tomography findings in lung adenocarcinoma. Bali Medical Journal, 8 (2). pp. 511-514. ISSN 2089-1180

	Text (Artikel) The Relationship between.pdf Download (179kB)
	Text (Similarity) The Relationship between Epidermal Growth Factor Receptor (EGFR) Mutation and Computed Tomography Findings in Lung Adenocarcinoma.pdf Download (1MB)
	Text (Peer Review) The Relationship between.pdf Download (1MB)

Abstract

Background: Adenocarcinoma is the highest histology subtype of lung cancer. Epidermal Growth Factor Receptor (EGFR) is a factor that can predict the prognosis or response to treatment in patients with lung adenocarcinoma. Adenocarcinomas with EGFR mutations generally have a component of Ground Glass Opacity (GGO), smaller size, oval shape, multiple nodal metastases, and distant metastases.  The aim of this study was to determine the relationship between EGFR mutations and CT scan images in pulmonary adenocarcinoma patients. Methods: This was a retrospective analytical study consisting of 92 samples, which were categorized into the mutation group (n = 62) and wild group (n = 30). This study was conducted at Dr. Soetomo General Hospital from January 2015 – December 2017. The assessed CT-Scan findings were tumor size, shape, density, lymph node size, pleural effusion, and metastasis presence. The relationship was analyzed using the chi-square test and considered significant if the p-value was < 0.05. Results: This study found a significant relationship between EGFR mutations status with tumor size ≤ 3 cm (p = 0.02), lymph node size < 1.5 cm (p = < 0.001) and metastasis (p = 0.026). However, tumor density, tumor form, and pleural effusion did not have significant relationship with EGFR mutation. Conclusion: Tumor size ≤ 3 cm, lymph node size < 1.5 cm and presence of metastasis can be found in EGFR mutations pulmonary adenocarcinoma patients.

Actions (login required)

View Item